Atherosclerosis
Volume 143, Issue 2 , Pages 335-340 , April 1999

Demonstration of the presence of lipid peroxide-modified proteins in human atherosclerotic lesions using a novel lipid peroxide-modified anti-peptide antibody

  • Jong G. Kim

      Affiliations

    • Department of Gynecology and Obstetrics, Emory University, Atlanta, GA 30322, USA
    • ,
  • W.Robert Taylor

      Affiliations

    • Division of Cardiology, Department of Medicine, Emory University, Atlanta, GA 30322 and Veterans Affairs Medical Center, Decatur, GA 30033, USA
    • ,
  • Sampath Parthasarathy

      Affiliations

    • Department of Gynecology and Obstetrics, Emory University, Atlanta, GA 30322, USA
    • Corresponding Author InformationCorresponding author. Present address: Department of Gynecology and Obstetrics, Emory University School of Medicine, Atlanta, GA 30322, USA. Tel.: +1-404-727-8604; fax: +1-404-727-8615

Received 14 April 1998 ,Revised 4 November 1998 ,Accepted 1 December 1998.

References 

  1. Haberland ME, Fong D, Cheng L. Malondialdehyde-altered protein occurs in the atheroma of Watanabe heritable hyperlipidemic rabbits. Science. 1988;241:215–218
  2. Palinski W, Rosenfeld ME, Yla Herttuala S, Gurtner GC, Socher SS, Butler SW, et al. Low density lipoprotein undergoes oxidative modification in vivo. Proc Natl Acad Sci USA. 1989;86:1372–1376
  3. Rosenfeld ME, Palinski W, Yla Herttuala S, Butler S, Witztum JL. Distribution of oxidation specific lipid–protein adducts and apolipoprotein B in atherosclerotic lesions of varying severity from WHHL rabbits. Arteriosclerosis. 1990;10:336–349
  4. Palinski W, Ord VA, Plump AS, Breslow JL, Steinberg D, Witztum JL. ApoE-deficient mice are a model of lipoprotein oxidation in atherogenesis. Demonstration of oxidation-specific epitopes in lesions and high titers of autoantibodies to malondialdehyde–lysine in serum. Arterioscler Thromb. 1994;14:605–616
  5. Holvoet P, Perez G, Zhao Z, Brouwers E, Berner H, Collen D. Malondialdehyde-modified low density lipoproteins in patients with atherosclerotic disease. J Clin Invest. 1995;95:2611–2619
  6. Jurgens G, Chen Q, Esterbauer H, Mair S, Ledinski G, Dinges HP. Immunostaining of human autopsy aortas with antibodies to modified apolipoprotein B and apoprotein(a). Arterioscler Thromb. 1993;13:1689–1699
  7. Hazell LJ, Arnold L, Flowers D, Waeg G, Malle E, Stocker R. Presence of hypochlorite-modified proteins in human atherosclerotic lesions. J Clin Invest. 1996;97:1535–1544
  8. Boyd HC, Gown AM, Wolfbauer G, Chait A. Direct evidence for a protein recognized by a monoclonal antibody against oxidatively modified LDL in atherosclerotic lesions from a Watanabe heritable hyperlipidemic rabbit. Am J Pathol. 1989;135:815–825
  9. Itabe H, Takeshima E, Iwasaki H, Kimura J, Yoshida Y, Imanaka T, et al. A monoclonal antibody against oxidized lipoprotein recognizes foam cells in atherosclerotic lesions. J Biol Chem. 1994;269:15274–15279
  10. Hammer A, Kager G, Dohr G, Rabl H, Ghassempur I, Jurgens G. Generation, characterization, and histochemical application of monoclonal antibodies selectively recognizing oxidatively modified apoB-containing serum lipoproteins. Arterioscler Thromb Vasc Biol. 1995;15:704–713
  11. Kim JG, Sabbagh F, Santanam N, Wilcox JN, Medford RM, Parthasarathy S. Generation of a polyclonal antibody against lipid peroxide-mediated proteins. Free Radic Biol Med. 1997;23:251–259
  12. Torzewski M, Klouche M, Hock J, Meßner M, Dorweiler B, Torzewski J, et al. Immunohistochemical demonstration of enzymatically modified human LDL and its colocalization with the terminal complement complex in the early atherosclerotic lesion. Arterioscler Thromb Vasc Biol. 1998;18:369–378
  13. Hoff HF, Heideman CL, Jackson RL, Bayardo RJ, Kim HS, Gotto AM. Localization patterns of plasma apolipoproteins in human atherosclerotic lesions. Circ Res. 1975;37:72–79
  14. Dell A, Morris HR, Easton RL, Panico M, Patankar M, Oehniger S, et al. Structural analysis of the oligosaccharides derived from glycodelin, a human glycoprotein with potent immunosuppresive and contraceptive activities. J Biol Chem. 1995;270:24116–24126
  15. Poddar AS, Kim JG, Gill KP, Bates BN, Santanam N, Rock JA, et al. Generation and characterization of a polyclonal antipeptide antibody to human glycodelin. Fertil Steril. 1998;69:543–548
  16. Beetens JR, Coene MC, Verheyen A, Zonnekeyn L, Herman AG. Influence of vitamin C on the metabolism of arachidonic acid and the development of aortic lesions during experimental atherosclerosis in rabbits. Biomed Biochim Acta. 1984;43:S273–S276
  17. Fruebis J, Parthasarathy S, Steinberg D. Evidence for a concerted reaction between lipid hydroperoxides and polypeptides. Proc Natl Acad Sci USA. 1992;89:10588–10592
  18. Parthasarathy S. Lipid peroxidation-induced protein modifications in the oxidation of low density lipoprotein. In:  Packer L,  Cadenas E editor. Biological oxidants and antioxidants. Stuttgart: Hippokrates Verlag; 1994;p. 255–259
  19. Fong LG, Parthasarathy S, Witztum JL, Steinberg D. Nonenzymatic oxidative cleavage of peptide bonds in apoprotein B-100. J Lipid Res. 1987;28:1466–1477

PII: S0021-9150(98)00320-7

Atherosclerosis
Volume 143, Issue 2 , Pages 335-340 , April 1999

Article Tools

* Image Usage & Resolution